Kalvista Pharmaceuticals Inc (KALV)

$11.93 +0.27 (2.32%)
Market Cap 593.11M
Revenue (ttm) 0.00
Net Income (ttm) -126.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 413,600
Avg Vol 593,452
Day's Range N/A - N/A
Shares Out 49.72M
Stochastic %K 39%
Beta 0.05
Analysts Strong Sell
Price Target $26.33

Latest News on KALV

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025, 7:00 AM EDT - 16 days ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

Apr 30, 2025, 7:00 AM EDT - 18 days ago

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

KalVista: Poised For Rare Disease Transformation

Apr 12, 2025, 12:42 AM EDT - 5 weeks ago

KalVista: Poised For Rare Disease Transformation

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

Apr 8, 2025, 6:30 AM EDT - 5 weeks ago

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:00 AM EDT - 6 weeks ago

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

Mar 25, 2025, 7:00 AM EDT - 7 weeks ago

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Mar 12, 2025, 7:00 AM EDT - 2 months ago

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Mar 10, 2025, 7:00 AM EDT - 2 months ago

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Mar 3, 2025, 7:00 AM EST - 2 months ago

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Feb 24, 2025, 7:00 AM EST - 2 months ago

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Feb 21, 2025, 7:00 AM EST - 3 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

Feb 10, 2025, 7:00 AM EST - 3 months ago

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

Jan 21, 2025, 7:00 AM EST - 4 months ago

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025

Dec 18, 2024, 1:46 PM EST - 5 months ago

KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025

KalVista Appoints Jeb Ledell as Chief Operating Officer

Dec 16, 2024, 7:00 AM EST - 5 months ago

KalVista Appoints Jeb Ledell as Chief Operating Officer

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

Dec 5, 2024, 6:30 AM EST - 5 months ago

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

Nov 26, 2024, 7:00 AM EST - 6 months ago

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

Nov 4, 2024, 7:05 AM EST - 6 months ago

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

Nov 4, 2024, 7:00 AM EST - 6 months ago

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

Oct 28, 2024, 6:30 AM EDT - 7 months ago

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

Oct 18, 2024, 6:30 AM EDT - 7 months ago

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum

Oct 4, 2024, 12:29 PM EDT - 8 months ago

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

Sep 30, 2024, 6:30 AM EDT - 8 months ago

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)

Sep 26, 2024, 6:30 AM EDT - 8 months ago

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:00 AM EDT - 8 months ago

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

KalVista Appoints Brian Piekos as Chief Financial Officer

Sep 10, 2024, 6:30 AM EDT - 8 months ago

KalVista Appoints Brian Piekos as Chief Financial Officer

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024

Sep 6, 2024, 6:30 AM EDT - 9 months ago

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

Sep 5, 2024, 6:30 AM EDT - 9 months ago

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

Sep 3, 2024, 6:30 AM EDT - 9 months ago

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium

Aug 29, 2024, 6:30 AM EDT - 9 months ago

KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium

KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

Aug 15, 2024, 6:30 AM EDT - 9 months ago

KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

Jul 11, 2024, 6:30 AM EDT - 11 months ago

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

Jun 27, 2024, 6:30 AM EDT - 11 months ago

KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

Jun 24, 2024, 2:53 AM EDT - 11 months ago

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema

Jun 18, 2024, 6:30 AM EDT - 11 months ago

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

Jun 6, 2024, 6:30 AM EDT - 1 year ago

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

Jun 3, 2024, 6:30 AM EDT - 1 year ago

KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

May 31, 2024, 12:15 PM EDT - 1 year ago

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024

May 24, 2024, 6:30 AM EDT - 1 year ago

KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

May 1, 2024, 6:30 AM EDT - 1 year ago

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

Apr 22, 2024, 6:30 AM EDT - 1 year ago

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 6:30 AM EDT - 1 year ago

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

Mar 18, 2024, 6:30 AM EDT - 1 year ago

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

Mar 12, 2024, 6:30 AM EDT - 1 year ago

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

Mar 8, 2024, 6:30 AM EST - 1 year ago

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

Mar 7, 2024, 6:30 AM EST - 1 year ago

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

Mar 6, 2024, 6:30 AM EST - 1 year ago

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 27, 2024, 6:30 AM EST - 1 year ago

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 26, 2024, 6:30 AM EST - 1 year ago

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

Feb 20, 2024, 6:30 AM EST - 1 year ago

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat